Department of Neurology & Psychiatry, St Louis University School of Medicine, MO, USA.
Am J Alzheimers Dis Other Demen. 2011 Feb;26(1):65-71. doi: 10.1177/1533317510391240.
Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer's disease (AD).
Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm(2)]), rivastigmine capsules (6 mg twice daily), or placebo, and impact on activities of daily living (ADLs) was assessed utilizing 3 subscales: basic, high-level function, and autonomy.
At week 24, both rivastigmine groups demonstrated significantly superior performance in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score versus placebo (rivastigmine patch, P = .013; capsules, P = .039). Overall, both rivastigmine formulations provided benefits in ADL subscales. For basic ADLs, rivastigmine capsules performed significantly better than placebo (P = .012). For high-level function ADLs, rivastigmine patch performed better than placebo (P = .056). For autonomy ADLs, rivastigmine patch performed significantly better than placebo (P = .017).
Rivastigmine patches and capsules provide significant effects in both total and subscale ADLs in patients with probable AD.
与利伐斯的明胶囊相比，利伐斯的明贴片在可能患有阿尔茨海默病（AD）的患者中具有相似的疗效，且胃肠道副作用发生率更低。
对一项为期 24 周、前瞻性、国际性、随机、双盲、安慰剂对照和活性对照试验进行事后分析。有可能性 AD 的患者（n=892）接受利伐斯的明透皮贴片（9.5 毫克/24 小时[10 平方厘米]）、利伐斯的明胶囊（6 毫克，每日两次）或安慰剂治疗，并利用日常生活活动（ADL）的 3 个亚量表评估对其的影响：基本、高级功能和自主。
在第 24 周，与安慰剂相比，利伐斯的明两组在阿尔茨海默病合作研究-日常生活活动（ADCS-ADL）总分方面均表现出明显的优越性（利伐斯的明贴片，P=0.013；胶囊，P=0.039）。总体而言，两种利伐斯的明制剂在 ADL 亚量表中都提供了益处。对于基本的 ADL，利伐斯的明胶囊的表现明显优于安慰剂（P=0.012）。对于高级功能 ADL，利伐斯的明贴片的表现优于安慰剂（P=0.056）。对于自主 ADL，利伐斯的明贴片的表现明显优于安慰剂（P=0.017）。
利伐斯的明贴片和胶囊在可能患有 AD 的患者中对总 ADL 和亚量表 ADL 均有显著作用。
